Cabaletta Bio, Inc.

Historical 13F Holders

Symbol
CABA
CUSIP
12674W109
All holders as of
Q2 2026
Type
Equity
Class
COM
Reported Value, Excluding Options
Total Filings

13D/G Filers

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Each filer's latest filing for 12674W109 since 12/18/2024, largest first.

Filer % of Class Filed
T. Rowe Price Investment Management, Inc. 13G/A 11.6% 8/14/2026
Event 6/30/2026
Jennison Associates LLC 13G/A 11.4% 6/4/2026
Event 5/29/2026
Prudential Financial Inc 13G/A 11.4% 6/5/2026
Event 5/31/2026
Bain Capital Life Sciences Opportunities III, LP 13G/A 10.0% 8/14/2026
Event 6/30/2026
Adage Capital Management, L.P. 13G/A
8.4% 8/12/2026
Event 6/30/2026
Cormorant Asset Management, LP 13G/A
6.0% 8/14/2026
Event 6/30/2026
BlackRock, Inc. 13G 5.9% 7/27/2026
Event 6/30/2026
Norges Bank 13G 5.4% 8/12/2026
Event 6/30/2026
Vanguard Capital Management LLC 13G 5.1% 7/31/2026
Event 6/30/2026
Under 5%, checked the "5 percent or less" box, or amended by a later filing (5)
Alyeska Investment Group, L.P. 13G/A
4.7% 2/17/2026
Event 12/31/2025
Vanguard Group Inc 13G/A 3.8% 7/29/2025
Event 6/30/2025
Citadel Advisors LLC 13G/A
3.4% 11/14/2025
Event 9/30/2025
Nichtberger Steven 13G/A 3.3% 8/11/2025
Event 6/30/2025
Millennium Management LLC 13G/A
1.3% 7/23/2026
Event 6/30/2026

13F Holders by Quarter

Period Filings Shares, Excl. Options Value, Excl. Options
2026 Q3 2 1.26 k $2.42 k
2026 Q2 151 159 M $494 M
2026 Q1 118 84.7 M $228 M
2025 Q4 101 80.3 M $176 M
2025 Q3 83 72.2 M $169 M
2025 Q2 93 72.8 M $111 M
2025 Q1 99 36.3 M $50.3 M
2024 Q4 115 38.4 M $87.2 M
2024 Q3 128 48.3 M $228 M
2024 Q2 152 52.3 M $391 M
2024 Q1 177 53.0 M $904 M
2023 Q4 142 49.2 M $1.12 B
2023 Q3 103 40.9 M $623 M
2023 Q2 90 36.4 M $470 M
2023 Q1 76 24.7 M $204 M
2022 Q4 66 20.0 M $185 M
2022 Q3 59 11.9 M $7.76 M
2022 Q2 56 16.8 M $17.8 M
2022 Q1 66 18.2 M $36.9 M
2021 Q4 76 18.3 M $69.4 M
2021 Q3 65 17.4 M $211 M
2021 Q2 67 15.8 M $135 M
2021 Q1 73 16.2 M $180 M
2020 Q4 57 16.2 M $202 M
2020 Q3 55 16.4 M $177 M
2020 Q2 53 16.4 M $183 M
2020 Q1 43 16.1 M $117 M
2019 Q4 42 16.4 M $229 M